Drug maker Lupin has launched 40 mg variant of Duloxetine delayed-release capsule in the US market. It is prescribed for depression.
Lupin has 20% market share in Duloxetine sales in the US and is the only company to introduce the 40 mg variant, a company spokesperson said. Currently the drug is available in 20 mg, 30 mg and 60 mg variants and its total market size in the US is about $1.05 billion.
"Lupin is excited to bring this new strength to the market as it adds to the currently available dosage options for greater flexibility of treatment," the company said in a statement today.
US business contributes to about 45% of its topline and its sales grew 11% to $891 million in last fiscal. In July it acquired generic drug maker Gavis in a $880 million deal to grow its US business.
